Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KRYS – Krystal Biotech, Inc.

Float Short %

10.75

Margin Of Safety %

-16

Put/Call OI Ratio

0.39

EPS Next Q Diff

-0.95

EPS Last/This Y

3.42

EPS This/Next Y

1.91

Price

281.55

Target Price

281.3

Analyst Recom

1

Performance Q

51.02

Relative Volume

1.06

Beta

0.49

Ticker: KRYS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26KRYS252.420.332.263364
2025-12-29KRYS253.920.320.063364
2025-12-30KRYS248.160.302.503514
2025-12-31KRYS246.520.311.003529
2026-01-02KRYS246.640.351.693636
2026-01-05KRYS244.660.3516.613629
2026-01-06KRYS249.260.530.004132
2026-01-07KRYS246.150.440.034692
2026-01-08KRYS248.450.441.444674
2026-01-09KRYS261.40.560.175131
2026-01-12KRYS272.550.350.165775
2026-01-13KRYS2920.370.465871
2026-01-14KRYS291.890.390.025742
2026-01-15KRYS282.330.350.626271
2026-01-16KRYS284.750.340.556276
2026-01-20KRYS275.080.410.214892
2026-01-21KRYS285.650.400.044936
2026-01-22KRYS289.490.400.004969
2026-01-23KRYS281.620.393.755057
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26KRYS252.355.0212.26.54
2025-12-29KRYS253.745.0213.06.54
2025-12-30KRYS248.045.0201.46.54
2025-12-31KRYS246.545.0208.26.54
2026-01-02KRYS246.655.0210.76.54
2026-01-05KRYS244.745.0206.86.54
2026-01-06KRYS249.265.0218.16.54
2026-01-07KRYS246.265.0205.36.54
2026-01-08KRYS248.745.0214.46.54
2026-01-09KRYS261.585.0231.36.54
2026-01-12KRYS272.605.0227.96.54
2026-01-13KRYS291.805.0239.86.54
2026-01-14KRYS291.815.0210.36.54
2026-01-15KRYS282.265.0197.36.54
2026-01-16KRYS284.755.0214.46.54
2026-01-20KRYS274.795.0195.96.54
2026-01-21KRYS286.035.0227.16.54
2026-01-22KRYS289.175.0214.96.54
2026-01-23KRYS281.555.0199.36.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-26KRYS-4.691.9310.91
2025-12-29KRYS-4.691.9310.91
2025-12-30KRYS-4.691.9310.91
2025-12-31KRYS-4.691.9310.91
2026-01-02KRYS-4.691.9310.91
2026-01-05KRYS-4.691.9310.91
2026-01-06KRYS-4.691.9310.91
2026-01-07KRYS-4.691.9310.91
2026-01-08KRYS-4.691.9310.91
2026-01-09KRYS-4.691.9310.91
2026-01-12KRYS-4.251.9110.91
2026-01-13KRYS-4.051.9110.75
2026-01-14KRYS-4.051.9110.75
2026-01-15KRYS-4.051.9110.75
2026-01-16KRYS-4.051.9110.75
2026-01-20KRYS-2.402.8110.75
2026-01-21KRYS-2.402.8110.75
2026-01-22KRYS-2.402.8110.75
2026-01-23KRYS-2.402.8110.75
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

2.66

Avg. EPS Est. Current Quarter

1.61

Avg. EPS Est. Next Quarter

1.71

Insider Transactions

-2.4

Institutional Transactions

2.81

Beta

0.49

Average Sales Estimate Current Quarter

105

Average Sales Estimate Next Quarter

119

Fair Value

236.61

Quality Score

91

Growth Score

41

Sentiment Score

82

Actual DrawDown %

4.9

Max Drawdown 5-Year %

-53.4

Target Price

281.3

P/E

42.23

Forward P/E

36.37

PEG

0.72

P/S

21.88

P/B

7.17

P/Free Cash Flow

49.3

EPS

6.67

Average EPS Est. Cur. Y​

6.54

EPS Next Y. (Est.)

8.44

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

53.3

Relative Volume

1.06

Return on Equity vs Sector %

-9.8

Return on Equity vs Industry %

6.2

EPS 1 7Days Diff

0.5

EPS 1 30Days Diff

0.53

EBIT Estimation

199.3
Krystal Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading